Imatinib associated temporal bone osteonecrosis

Tyrosine kinase inhibitors have substantially improved survival in patients with gastrointestinal stromal tumors (GIST) and chronic myeloid leukemia (CML). We report the first association between long‐term imatinib use and temporal bone osteonecrosis, highlighting the importance of prompt ENT evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: McKenna, Dominic, Reddy, Ekambar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307993/
https://www.ncbi.nlm.nih.gov/pubmed/37397584
http://dx.doi.org/10.1002/ccr3.7611
Descripción
Sumario:Tyrosine kinase inhibitors have substantially improved survival in patients with gastrointestinal stromal tumors (GIST) and chronic myeloid leukemia (CML). We report the first association between long‐term imatinib use and temporal bone osteonecrosis, highlighting the importance of prompt ENT evaluation of such patients with new otological symptoms.

Ejemplares similares